Based on the Precigen Inc stock forecast from 3 analysts, the average analyst target price for Precigen Inc is USD 5.60 over the next 12 months. Precigen Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Precigen Inc is Bearish, which is based on 1 positive signals and 6 negative signals. At the last closing, Precigen Inc’s stock price was USD 1.24. Precigen Inc’s stock price has changed by -22.01% over the past week, -33.69% over the past month and -11.43% over the last year.
No recent analyst target price found for Precigen Inc
No recent average analyst rating found for Precigen Inc
Company Overview Precigen Inc
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ½ trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland. Read Less
Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two ...Read More
Frequently Asked Questions About Precigen Inc (PGEN) Stock
Based on ratings from 3 analysts Precigen Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on PGEN's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for PGEN is USD 5.60 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 4.
Unfortunately we do not have enough data on PGEN's stock to indicate if its overvalued.
The last closing price of PGEN's stock was USD 1.24.
The most recent market capitalization for PGEN is USD 0.51B.
Based on targets from 3 analysts, the average taret price for PGEN is projected at USD 5.60 over the next 12 months.
This means that PGEN's stock price may go up by +351.61% over the next 12 months.
We can't find any ETFs which contains Precigen Inc's stock.
As per our most recent records Precigen Inc has 202 Employees.
Precigen Inc's registered address is 20358 Seneca Meadows Parkway, Germantown, MD, United States, 20876.
You can get more information about it from Precigen Inc's website at https://precigen.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior Earnings Growth
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Negative free cash flow
The company had negative total free cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Frequently Asked Questions About Precigen Inc (PGEN) Stock
Based on ratings from 3 analysts Precigen Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Bearish. The stock has 5 buy, sell and hold ratings.
Unfortunately we do not have enough data on PGEN's stock to indicate if its a good dividend stock.
Based on targets from 3 analysts, the average taret price for PGEN is USD 5.60 over the next 12 months. The maximum analyst target price is USD 7 while the minimum anlayst target price is USD 4.
Unfortunately we do not have enough data on PGEN's stock to indicate if its overvalued.
The last closing price of PGEN's stock was USD 1.24.
The most recent market capitalization for PGEN is USD 0.51B.
Based on targets from 3 analysts, the average taret price for PGEN is projected at USD 5.60 over the next 12 months.
This means that PGEN's stock price may go up by +351.61% over the next 12 months.
We can't find any ETFs which contains Precigen Inc's stock.
As per our most recent records Precigen Inc has 202 Employees.
Precigen Inc's registered address is 20358 Seneca Meadows Parkway, Germantown, MD, United States, 20876.
You can get more information about it from Precigen Inc's website at https://precigen.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for PGEN !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
